A multicenter, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma

被引：0

作者：

Quach, Hang ^{[1
]}

Parmar, Gurdeep ^{[2
]}

Ocio, Enrique M. ^{[3
]}

Prince, H. Miles ^{[4
,5
]}

Oriol, Albert ^{[6
,7
]}

Crowther, Helen ^{[8
]}

Tsukada, Nobuhiro ^{[9
]}

Bories, Pierre ^{[10
]}

Madan, Sumit ^{[11
]}

Nathwani, Nitya ^{[12
]}

Sunami, Kazutaka ^{[13
]}

Semiond, Dorothee ^{[14
]}

Yu, Disa ^{[14
]}

Cordero, Paul ^{[15
]}

Mace, Sandrine ^{[16
]}

Suzan, Florence ^{[16
]}

Moreau, Philippe ^{[17
]}

机构：

[1] Univ Melbourne, St Vincents Hosp, Clin Hematol Serv, Melbourne, Australia

[2] Illawarra Canc Care Ctr, Wollongong, Australia

[3] Univ Cantabria, Hosp Univ Marques Valdecilla IDIVAL, Santander, Spain

[4] Epworth HealthCare, Mol Oncol & Canc Immunol, Melbourne, Australia

[5] Univ Melbourne, Melbourne, Australia

[6] Hosp Germans Trias i Pujol, Inst Catala Oncol, Barcelona, Spain

[7] Hosp Germans Trias i Pujol, Inst Josep Carreras, Barcelona, Spain

[8] Blacktown & Mt Druitt Hosp, Dept Paediat, Blacktown, NSW, Australia

[9] Japanese Red Cross Med Ctr, Dept Hematol, Tokyo, Japan

[10] Inst Univ Canc Toulouse, Inst Claudius Regaud, Inst Claudius Regaud, Toulouse, France

[11] Banner MD Anderson Canc Ctr, Gilbert, AZ USA

[12] City Hope Natl Med Ctr, Dept Hematol, Duarte, CA USA

[13] Natl Hosp Org Okayama Med Ctr, Dept Hematol, Okayama, Japan

[14] Sanofi, Res & Dev, Cambridge, MA USA

[15] Sanofi, Res & Dev, Reading, England

[16] Sanofi, Res & Dev, Vitry Sur Seine, France

[17] Univ Hosp Nantes, Dept Hematol, Nantes, France

来源：

HAEMATOLOGICA | 2024年 / 109卷 / 12期

关键词：

OPEN-LABEL;

D O I：

10.3324/haematol.2023.284730

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：4078 / 4082

页数：5

共 50 条

[1] Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design
Richardson, Paul G.
Attal, Michel
Campana, Frank
Le-Guennec, Solenn
Hui, Ai-Min
Risse, Marie-Laure
Corzo, Kathryn
Anderson, Kenneth C.
FUTURE ONCOLOGY, 2018, 14 (11) : 1035 - 1047
[2] A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma
Mikhael, Joseph
Richardson, Paul
Usmani, Saad Z.
Raje, Noopur
Bensinger, William
Karanes, Chatchada
Campana, Frank
Kanagavel, Dheepak
Dubin, Franck
Liu, Qianying
Semiond, Dorothee
Anderson, Kenneth
BLOOD, 2019, 134 (02) : 123 - 133
[3] Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial
Kumar, Sudhir
Sharma, Atul
Malik, Prabhat Singh
Gogia, Ajay
Pathak, Neha
Sahoo, Ranjit Kumar
Gupta, Ritu
Prasad, Chandra Prakash
Kumar, Lalit
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (02) : 288 - 297
[4] Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world: The retrospective IMAGE study
Decaux, Olivier
Fontan, Jean
Perrot, Aurore
Karlin, Lionel
Touzeau, Cyrille
Schulmann, Samantha
Manier, Salomon
Belhadj, Karim
Trebouet, Adrien
Zunic, Patricia
Schiano De Colella, Jean-Marc
Castel, Brice
van de Wyngaert, Zoe
Pica, Gian Matteo
Tiab, Mourad
Kuhnowski, Frederique
Bouketouche, Malek
Rigaudeau, Sophia
Benramdane, Riad
Tekle, Christina
Lafore, Radhia
Gaucher, Marianne
Corre, Jill
Leleu, Xavier
EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 113 (03) : 290 - 297
[5] Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study
Lesokhin, Alexander
LeBlanc, Richard
Dimopoulos, Meletios A.
Capra, Marcelo
Carlo-Stella, Carmelo
Karlin, Lionel
Castilloux, Jean-Francois
Forsberg, Peter
Parmar, Gurdeep
Tosikyan, Axel
Pour, Ludek
Ribrag, Vincent
Ribolla, Rossella
Abdallah, Al-Ola
Le Roux, Nadia
Dong, Liyan
van de Velde, Helgi
Mayrargue, Laurent
Lepine, Lucie
Mace, Sandrine
Moreau, Philippe
CANCER MEDICINE, 2023, 12 (09): : 10254 - 10266
[6] A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma
Martin, Thomas
Baz, Rachid
Benson, Don M.
Lendvai, Nikoletta
Wolf, Jeffrey
Munster, Pamela
Lesokhin, Alexander M.
Wack, Claudine
Charpentier, Eric
Campana, Frank
Vij, Ravi
BLOOD, 2017, 129 (25) : 3294 - 3303
[7] Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design
Moreau, Philippe
Dimopoulos, Meletios A.
Yong, Kwee
Mikhael, Joseph
Risse, Marie-Laure
Asset, Gaelle
Martin, Thomas
FUTURE ONCOLOGY, 2020, 16 (02) : 4347 - 4358
[8] Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma
Sun, Mingyuan
Jing, Hongmei
Qu, Xiaoyan
Dong, Fei
Li, Yi
Feng, Zhaoyi
Ziti-Ljajic, Samira
Semiond, Dorothee
Li, Lingyu
Qi, Junyuan
Qiu, Lugui
SCIENTIFIC REPORTS, 2024, 14 (01):
[9] Pomalidomide and Dexamethasone Are Effective in Relapsed or Refractory Multiple Myeloma in a Real-Life Setting: A Multicenter Retrospective Study in Taiwan
Hung, Yu-Chin
Gau, Jyh-Pyng
Huang, Shang-Yi
Ko, Bor-Sheng
Teng, Chieh-Lin Jerry
FRONTIERS IN ONCOLOGY, 2021, 11
[10] Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study
Sunami, Kazutaka
Suzuki, Kenshi
Ri, Masaki
Matsumoto, Morio
Shimazaki, Chihiro
Asaoku, Hideki
Shibayama, Hirohiko
Ishizawa, Kenichi
Takamatsu, Hiroyuki
Ikeda, Takashi
Maruyama, Dai
Kaneko, Hitomi
Uchiyama, Michihiro
Kiguchi, Toru
Iyama, Satoshi
Murakami, Hirokazu
Takahashi, Keishiro
Tada, Keisuke
Mace, Sandrine
Guillemin-Paveau, Helene
Iida, Shinsuke
CANCER SCIENCE, 2020, 111 (12) : 4526 - 4539

← 1 2 3 4 5 →